China Biologic Products Holdings Inc
China Biologic Products — Investor Presentation (April 2009)
28 slides from China Biologic Products's investor presentation, Apr 20, 2009

Slide 1: China Biologic Products, Inc. - April 2009
April 2009 & ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

Slide 2: Safe Harbor Statement
@ Safe Harbor Statement CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation includes or incorporates by reference statements that constitute forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21£ of the Securit

Slide 3: Equity Snapshot
@ .@ Equity Snapshot Ticker CBPO.OB Price (04/09/09): $3.00 Market Capitalization: $64.7 M Revenues (FY08): $46.8 M Net Income (FY08): $i20mM r Diluted EPS (FY08) $0.56 PIE (FYO8) 5.4X P. & China Biologic Products, Inc. 3 ed

Slide 4: Company Overview
@ Company Overview Largest non-state-owned producer of plasma-based biopharmaceutical companies in China + Fully integrated biologic products company with plasma collection, production and manufacturing research and development, and commercial operations + Three of 32 approved manufacturers + Equity

Slide 5: Plasma-Derived Therapeutics
@Plasma-Derived Therapeutics China Biologic is a fully-integrated plasma-based biopharmaceutical company Manufacturing (Eractionation) Plasma Collection Distribution a a : Beneficial proteins are Plasme-desived products jonors (paid an average o ith di icati nors (paid an average sepsrsted tore pleu

Slide 6: Investment Highlights
Investment Highlights Blood products cannot be substituted in many applications, including for medical emergencies, and prevention & treatment for some specific diseases such as hepatitis, rabies, tetanus, etc. on Revenue USD in Millions Multiple growth drivers including: 500 + Rising demand for pla

Slide 7: Growing Market Opportunity
Growing Market Opportunity ) a « Growth of the market for plasma based ; i 5 ae Market Size of Plasma- products in China has accelerated in 2 one beni fates cores oo recent years saa 20% « Spending on healthcare in China 500 20% continues to increase both in terms of 3, i annual spending and as a pe

Slide 8: Plasma Collection - Shandong Taibang
Plasma Collection - Shandong Taibang 2008 Total Collected Volume of Plasma in China has Declined Rapidly Due to Government Reform of Industry Collected Plasma in China Except ‘Shandong Taibang 97.0% Collected Plasma by Shandong Taibang Shandong Taibang sourcing from °° plasma stations: 3 2700 (Tons)

Slide 9: Attractive Acquisitions: Dalin and Huitian
Acquired a 90% controlling interest in Chongging Dalin Biologic Technologies, which represents an approximately 48.6% indirect interest in Qianfeng, Dalin’s 54% majority owned subsidiary *Guiyang, Guizhou Province *Currently 6 out of the 7 plasma stations in operation, collecting 250 tons of plasma

Slide 10: New China Biologic
ie New China Biologic Existing Plasma collection centers in operation Estimated annual plasma collection volume (tons) Plasma manufacturing facilities Plasma manufacturing capacity (tons) feg. 90% controling interest in Chongging Dalin Biologic Technologies, wich 4 0 t 48.6% interest in 2) Products,

Slide 11: Plasma Market: China vs. Developed Nations
Plasma Market: China vs. Developed Nations IVIG (Intravenous Region Albumin Immunoglobulin G) China 100kg tkg More developed 200-300Kg 40xg countries Range of Plasma Products Used Number of Human Various types of Region Plasma Products Albumin __ Immunoglobulin China More developed countries China B

Slide 12: New Mandates Strengthen Market Structure/Drive Consolidation
® New andates Strengthen Market St ture/Drive Consolidation Government Reform of Plasma-based Industry + Reform of blood collection stations in 2006 + GMP Certification reauired for blood collection stations, biopharmaceutical manufacturers + Restriction of imported products due to past outbreaks +

Slide 13: Product Revenue Mix
@Product Revenue Mix Increasing product diversification and growth in high margin specialty products) Three new products currently in clinical trials PRODUCT) % of 2007 Sales | % of 2008 Sales Human Albumin Human Immunoglobulin for Intravenous Injection Human Tetanus Immunoglobulin Others (1) China

Slide 14: Focus on R&D
Focus on R&D On-going R&D Objectives « Expand portfolio of plasma-based biopharmaceutical products « Maximize manufacturing efficiency and safety « Promote product safety through implementation of new technologies « Refine production technology on existing products & China Biologic Products, Inc. 14

Slide 15: New Product Pipeline
@ @New Product Pipeline Human Hepatitis B Immunoglobulin (pH 4) for Intravenous Injection Human Prothrombin Complex Concentrate Human Coagulation Factor VIII Human Fibrinogen Human Immunoglobulin for Intravenous Injection - 10% Approved to commence clinical trial (stage 8) Approved to commence clini

Slide 16: New Product Approval Process
@New)Product Approval Process Overview of SFDA Approval Process for New Plasma Products Stage Est. Time (Months) 1 Planning stage 1 2 Feasibility study and assumption clarification 2 3 Develop scope and technique for testing the new medicine 6 4 Preparation of a virus inactivation report and submiss

Slide 17: China Biologic's GMP certification was renewed
. China Biologic’s GMP certification was renewed in August 2008, China Biologic is the first company in the industry to pass the new version of GMP inspection GMP certification is granted by the SFDA and assures the quality, safety, and effectiveness of pharmaceutical products High barrier to entry:

Slide 18: One of first plasma-based manufacturers to receive GMP certification
One of first plasma-based manufacturers in China to receive GMP certification (1999); renewed in 2008 Awarded Advanced High-tech Enterprise Certification by the Ministry of Science and Technology of PRC (2006) Accepted into Double Hundred Project by Shandong Economic and Trade Committee (2007) Award

Slide 19: Management Profiles
Management Profiles Chao Ming Zhao, CEO * Chief Financial Officer of China operating subsidiary between September 2003 and May 2008 + Over 10 years of experience in finance, accounting and intemal control + Certified Accountant in the PRC and an international registered internal auditor + MBA in fin

Slide 20: A profitable, rapidly growing plasma-based biopharmaceutical products company in China
© , China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

Slide 21: Strong Profitable Growth
@ @strong Profitable Growth Revenue USD in Millions Gross Profit USD in Millions oss 60.0 40.0 32.7 20.0 10.0 ri | 40.0 2005 2006 2007 2008 2005 2006 2007 2008 Guidance 2009: a 2009 Full Year Range of Revenue : $90 to $100 million 2009 Full Year Range of Net Income : $18 a ‘© China Biologic Products

Slide 22: Rising Net Income
@ Rising Net Income (USS in Millions) EPS-Diluted & China Biologic Products, Inc. 22

Slide 23: Income Statement
Income Statement Consolidated Income Statement Fiscal Year Ended Dec 31 ($ in Millions) 2007 2006 Revenues 32.4 22.2 Gross Profit 32.7 22.5 126 Gross Margin 70.0% 69.3% 56.8% Operating income 20.3 12.8 6.2 Operating Margin 43.5% 39.5% 27.9% Net income 12.0 8.2 3.8 Net Margin 25.6% 25.2% 17.2% Wid. A

Slide 24: Balance Sheet
— @.o Balance Sheet Consolidated Balance Sheets, December 31, (Sin Millions) 2008 2007 , Cash $8.8 $5.0 Inventory $14.9 $9.5 Total Current Assets $25.2 $15.7 Total Assets $67.2 $33.3 Total Current Liabilities $19.3 $6.9 Total Stockholder’s Equity $37.8 $22.4 Total Liabilities & Stockholder’s Equit $

Slide 25: Peer Comparison
Revenue Stock Price 2008 Company Teker —(gaou2008) Revenues —«GFOwH—«ZOUBEPS PIE Hualan Biological go2997s2 $8.87 $69.8m 35.3% $0.13 48.3 31.3 Engineering Inc. Beijing Tiantan Biological Products 600161.ss $2.76 $98.9 m 28.2% $0.04 53.4 25.3 Corp. Ltd. Unisplendour Guhan Group Shanghai RAAS Blood Pr

Slide 26: Largest non-state-owned, fully-integrated producer of plasma-based biopharmaceuticals
Largest non-state-owned, fully-integrated producer of plasma-based biopharmaceutical companies in China Rapidly growing demand for plasma-based products Under penetrated, consolidating market Securing raw materials supply High barriers to entry with strict regulatory environment Growing portfolio of

Slide 27: Contact
Contact China Biologic Products Inc. CCG Investor Relations Inc. Y. Tristan Kuo No.14 East Hushan Road Taian City, Shandong 271000 PRC Tel: 86 538-6202306 !R@chinabiologic.com Legal Counsel Pillsbury Winthrop Shaw Pittman LLP Crocker Coulson, President 1325 Avenue of the Americas, Suite 2800 New Yor

Slide 28: April 2009
April 2009 , China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China
Source: SEC EDGAR · 8-K filed Apr 20, 2009
More decks from China Biologic Products Holdings Inc
36th Annual J.P. Morgan Healthcare Conference 201837 slides · Jan 8, 2018
35th Annual J.P. Morgan Healthcare Conference 201731 slides · Jan 4, 2017
34th Annual J.P. Morgan Healthcare Conference 201631 slides · Jan 4, 2016
Investor Presentation (June 2012)49 slides · Jun 4, 2012
Investor Presentation (June 2011)28 slides · Jun 7, 2011
Investor Presentation (March 2011)28 slides · Mar 7, 2011